BioCryst (BCRX) Advances Oral Plasma Kallikrein Inhibitors
Tweet Send to a Friend
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that it has selected two optimized plasma kallikrein inhibitors to advance into preclinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE